VBWG
Data alert

MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function

Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women. Now, a new analysis by Ghali and coworkers of women in the Metoprolol Controlledrelease Randomized Intervention Trial in Heart Failure (MERIT-HF) provides evidence that women with HF and reduced left ventricular ejection fractions (LVEF) live longer and are hospitalized less frequently if they receive ß-blocker therapy.1 The benefits of ß-blockade in women were similar to those in men.

References are listed at the end of the Data Alert.





DA9.ppt

Download DA9.ppt (5 slides - 0.7MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


blockadecreatedHFMERITrepresentationuncertaintyventricular

Related at vwbg.org

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

MERIT-HF: Impact of ß-blocker dose on outcomes in patients with heart failure

In a post hoc subgroup analysis, the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure) researchers examined the relation of ß-blocker dose to clinical outcomes.
More related